Cercar
10/10/2025
Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)
Yang, JCH, Wang, MZ, Doucet, L, Fan, Y, Lv, DQ, Sun, ML, Huang, DZ, Greillier, L, Planchard, D, Hong, QY, Mazieres, J, Felip, E, Li, XY, Hu, Y, Fang, J, Bazhenova, L, Ghiringhelli, F, Dols, MAC, Rodriguez, LPA, Bearz, A, Pellini, B, Kim, YJ, Bosch-Barrera, J, Shim, BY, Luo, YH, Tiseo, M, Yang, TY, Carcereny, E, Memmott, RM, Zalcman, G, Carpeno, JD, Di Noia, V, Parra, HS, Streich, G, Lee, DH, Shum, E, Han, JY, Jaime, JC, Brungs, D, John, T, D'Arcangelo, M, Joaquin, AB, Liu, GF, Antonuzzo, L, Hinojal, GF, Le, XN, Zheng, L, Jänne, PA. Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B). JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(29)DOI:10.1200/JCO-25-00788. PMID:40923280. IF:41.900(Q1/1D).
01/10/2025
Oncological needs in transgender patients
de la Peña, FA, Martínez-Ramos, D, Juan-Vidal, O, Gómez-Balaguer, M, Miguélez, M, Páez, D, Arrazubi, V, González, CH. Oncological needs in transgender patients. Clinical & Translational Oncology. 2025; 27(10)DOI:10.1007/s12094-025-03917-x. PMID:40251439. IF:2.500(Q3/6D).
01/10/2025
Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study
Suárez, C, Torras, OR, Barrera, RM, Sánchez, AR, Palacios, GA, Manshino, AMB, Núñez, NF, Vidal, MJM, Carbonero, IG, Calvo, OF, Sarrió, RG, Herrero, GC, Afonso, JA, Fita, MJJ, Padró, JG, Quintela, ML, Rodriguez-Vida, A, Perez, CH, Colmenero, AM, Martin, RC, de España, CG, Palau, CM, Ortega, EM, Gallardo, E. Effectiveness and Safety of Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma in Spanish and Portuguese Real-world Practice: The SOGUG-SPRWEC Study. Clinical Genitourinary Cancer. 2025; 23(5)DOI:10.1016/j.clgc.2025.102402. PMID:40830022. IF:2.700(Q2/3D).
01/10/2025
Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials
Palmerini, E, Meazza, C, Tamburini, A, Márquez-Vega, C, Bisogno, G, Fagioli, F, Ferraresi, V, Milano, GM, Coccoli, L, Rubio-San-Simón, A, Gallego, O, Riestra, MEL, Manzitti, C, Mora, J, Vaz-Salgado, MA, Luksch, R, Mata, C, Pierini, M, Carretta, E, Cesari, M, Paioli, A, Marrari, A, Scotlandi, K, Serra, M, Asaftei, SD, Gambarotti, M, Picci, P, Ferrari, S, Valverde, C, Ibrahim, T, Broto, JM. Is There a Role for Mifamurtide in Nonmetastatic High-Grade Osteosarcoma? Results From the Italian Sarcoma Group (ISG/OS-2) and Spanish Sarcoma Group (GEIS-33) Trials. JOURNAL OF CLINICAL ONCOLOGY. 2025; 43(28)DOI:10.1200/JCO-25-00210. PMID:40825172. IF:41.900(Q1/1D).